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Allogeneic natural killer (NK) cells are used for adoptive immunotherapy after stem cell
transplantation. In order to overcome technical limitations in NK cell purification and activa-
tion, the following study investigates the impact of different variables on NK cell recovery,
cytotoxicity, and T-cell depletion during good manufacturing practice (GMP)-grade NK cell
selection. Forty NK cell products were derived from 54 unstimulated donor leukaphereses
using immunomagnetic CD3T-cell depletion, followed by a CD56 cell enrichment step. For
T-cell depletion, either the depletion 2.1 program in single or double procedure (D2.11depl,
n=18; D2.12depl, n=13) or the faster depletion 3.1 (D3.1, n=9) was used on the Clini-
MACS instrument. Seventeen purified NK cell products were activated in vitro by IL-2 for
12 days. The whole process resulted in a median number of 7.59×108 CD56+CD3− cells
with both purity and viability of 94%, respectively. The T-cell depletion was significantly
better using D2.11depl/2depl compared to D3.1 (log 4.6/log 4.9 vs. log 3.7; p<0.01) and
double procedure in two stages led always to residualT cells below 0.1%. In contrast D3.1
was superior to D2.11depl/2depl with regard to recovery of CD56+CD3− NK cells (68% vs.
41%/38%). Concomitant monocytes and especially IL-2 activation led to increased NK cell
activity against malignant target cells compared to unstimulated NK cells, which correlated
with both up-regulation of natural cytotoxicity receptors and intracellular signaling. Overall,
wide variations in the NK cell expansion rate and the distribution of NK cell subpopulations
were found. In conclusion, our results indicate that GMP-grade purification of NK cells
might be improved by a sequential processing of T-cell depletion program D2.1 and D3.1.
In addition NK cell expansion protocols need to be further optimized.
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INTRODUCTION
Natural killer (NK) cells play an important role in the immune
response against leukemia or tumor cells after stem cell trans-
plantation. They represent a promising therapeutic option for
patients with various types of malignant disease (Passweg et al.,
2006; Rubnitz et al., 2010). NK cells are able to exert a graft-vs.-
leukemia/tumor (GvL/T) effect without concomitant severe graft
vs. host disease (GvHD) (Ruggeri et al., 2002). Phenotypically,
they express CD56, an isoform of the neural cell adhesion mol-
ecule, on their surface simultaneously lacking the CD3 antigen.
They can be further divided into a CD56dimCD16+ population of
about 90% that has cytotoxic activity, and a CD56brightCD16dim/−
subpopulation with immunoregulatory properties. They prolifer-
ate in response to IL-2 and produce large quantities of cytokines,
among these IFN-γ, TNF-α, TNF-β, IL-10, and IL-13. A set of
surface receptors on each cell can either induce or inhibit the
cytotoxic response. Compared to resting NK cells, cytotoxicity
of IL-2 activated NK cells is enhanced by up-regulation of the
natural cytotoxicity receptors (NCRs) NKp30, NKp44, NKp46,
and the NK group 2D (NKG2D) receptor (Moretta et al.,
2001; Farag et al., 2002; Lanier, 2005; Ljunggren and Malmberg,
2007).
Adoptive immunotherapy with unstimulated or IL-2 activated
donor NK cell infusions (NK-DLI) is currently used in patients
with high risk of relapse after haploidentical stem cell transplan-
tation (haploSCT) (Rubnitz et al., 2010; Brehm et al., 2011; Stern
et al., 2013). Preliminary results are encouraging. Yet, crucial issues
remain unanswered, among these, both, clinical questions (i.e.,
suitable target diseases and timing of NK-DLI) and questions
regarding the processing of the original cell product (i.e., optimal
T-cell depletion and NK cell enrichment). Although first protocols
for clinical grade NK cell enrichment and culture observing good
manufacturing practice (GMP) have been established, so far, no
standard procedure has been defined.
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Here, we evaluate variables that influence T cell depletion and
overall purity, expansion, and cytotoxic activity of clinical grade
NK cell products.
MATERIALS AND METHODS
NK CELL STUDY
Both, children and adults with high-risk malignancies received
unstimulated NK-DLIs at days +3, +40, and +100 or IL-2 stim-
ulated NK-DLI at days +40 and +100 following haploSCT as
described previously (Koehl et al., 2005; Brehm et al., 2011; Stern
et al., 2013). For this purpose, we enriched 54 apheresis prod-
ucts from 33 healthy donors, aiming at a cell dose of greater
than or equal to 1× 107 CD56+CD3− NK cells/kg with less than
1× 105 CD3+ T cells/kg recipient´s body weight (BW) at each
timepoint. Informed consent was obtained from the donors after
approval of the local ethics committee for both a small NK-DLI
feasibility study and a subsequent bi-center phase I/II trial reg-
istered at clinicaltrials.gov (NCT01386619). Apheresis products
were collected from 22 male and 18 female donors. Median age
and BW of the donors were 39 years (range: 27–53) and 75 kg
(range: 62–123), respectively.
The apheresis products underwent a single or double CD3
depletion step detailed below followed by a CD56 enrichment
step. Seventeen NK cell products were activated and expanded
with 1000 U/ml rhIL-2. GMP was observed throughout.
CLINICAL GRADE NK CELL PURIFICATION
Fifty-four steady-state leukaphereses were carried out using a Cobe
Spectra cell separator (Gambro BCT, Munich, Germany). In 26
cases, we processed a single leukapheresis product, while in 14
cases, 2 leukapheresis products each were pooled. To optimize
manufacturing of NK cell products three different methods were
used for purification as shown in Figure 1; (A) two T-cell deple-
tion steps using the CliniMACS depletion program 2.1 (D2.12depl),
(B) one T-cell depletion step with the same program (D2.11depl),
and (C) one T-cell depletion step using the CliniMACS deple-
tion program 3.1 (D3.11depl). Clinical grade enrichment of NK
cells was accomplished by CD3+ depletion followed by CD56+
selection. In case that we processed a single leukapheresis product,
the total enrichment procedure lasted two working days. In the
cases that two leukapheresis products were processed, each under-
went CD3+ depletion singly. The first was depleted immediately
or in exceptional cases the next morning after apheresis, the second
immediately on the day after collection. Then, the products were
pooled. In 13 cases, an additional T-cell depletion step ensued.
Afterward, CD56+ positive selection was done.
In detail: for the actual immunomagnetic procedure, an
unstimulated leukapheresis product was washed twice to remove
platelets with CliniMACS buffer (Miltenyi Biotech, Bergisch Glad-
bach, Germany) supplemented with 0.4% human serum albumin
(Red Cross Blood Donor Service, Baden-Württemberg-Hessen,
Germany). Then, 5 ml of Intraglobin (Biotest, Dreieich, Ger-
many) was added and incubated for 5 min to reduce non-specific
antibody binding. Subsequently, we added the CliniMACS CD3
Reagent (Miltenyi Biotec) and incubated the cells for 30 min, using
one vial of reagent for either total nucleated cell (TNC) counts
of up to 4× 1010 and CD3+ cell counts of up to 1.5× 1010. An
additional vial was employed for up to twice the numbers. After
two washing steps, CD3+ cells were immunomagnetically depleted
on the CliniMACS instrument using either the program “DEPLE-
TION 2.1” and a LS tubing set (Miltenyi Biotech) or the program
“DEPLETION 3.1” and a DTS tubing set (Miltenyi Biotech). A
second depletion run of the NK cell containing negative frac-
tion without additional labeling step was employed to remove
any residual T cells in 13 of the 31 cases that we used the program
“DEPLETION 2.1,” while in 18 of 31 instances, only one T-cell
depletion run was done. In the cases that we used “DEPLETION
3.1,” no additional depletion run was performed. Finally, the T-cell
depleted cell fraction was concentrated and labeled with clinical
grade CD56 MicroBeads® (MiltenyiBiotech) for 30 min (one vial
for TNC numbers of up to 4× 1010 and CD56+ cell numbers of
up to 1× 1010) and washed. Then, the CD56+CD3− NK cells were
enriched using the program “ENRICHMENT 1.1.” All steps were
performed in a closed system according to GMP.
EXPANSION AND ACTIVATION OF NK CELLS
The purified CD56+CD3− NK cells were suspended at
1× 106 cells/ml in X-VIVO 10 media (Lonza, Basel, Switzer-
land) supplemented with 5% heat-inactivated human fresh frozen
plasma (FFP) and 1000 U/ml rhIL-2 (Proleukin® Novartis Pharma
Nürnberg, Germany) for up to 12 days in GMP-grade VueLife®
culture bags (Cellgenix, Freiburg, Germany). In the context of fea-
sibility assessment, the cells from the first three donors, only, were
cultured in 175 cm3 culture flasks (Nunc, Wiesbaden, Germany).
In each case, fresh media were added every 3 days. To optimize
NK cell expansion, we carried out a series of small scale experi-
ments comparing the use of 1000 U/ml rhIL-2 with combined IL-2
(100 U/ml) and IL-15 (10 ng/ml) stimulation. For cryopreserva-
tion, NK cells were concentrated and resuspended in X-VIVO 10
media diluted 1:2 with 20% dimethyl sulfoxide (DMSO).
FLOW CYTOMETRIC QUALITY CONTROL ANALYSIS
Samples were drawn after leukapheresis and after each depletion
and selection as well as every third day during stimulation to
monitor cell content and viability. Phenotyping and evaluation
of cytotoxicity was performed by flow cytometry. We evaluated
the samples for NK cell purity, cell viability, CD56dimCD16+ and
CD56brightCD16dim/− NK cell subpopulations, residual T cells,
monocytes, dendritic cells (DCs) including the subtypes myeloid
DCs (mDCs) and plasmacytoid DCs (pDCs), and NK cell cyto-
toxic activity. Absolute cell counts were measured by a single-
platform approach using Flow-Count™ fluorospheres (Beckman
Coulter, Marseille, France). NK and T cells were gated as previ-
ously published according to an adapted version of the ISHAGE
single-platform stem cell enumeration method using low scatter,
high expression of CD3 and CD45 antigens, CD56 expression,
and 7-amino-actinomycin D (7-AAD) for assessment of viability
(Koehl et al., 2008). An automated lyse/no-wash procedure was
used with a fixation step on a TQ-Prep™ Workstation (Beck-
man Coulter, Krefeld, Germany). CD45-FITC/CD3-PE/CD14-
ECD/7-AAD/CD56-PC7 (Figure 2A) and CD45-FITC/CD3-
PE/CD16-ECD/7-AAD/CD56-PC7 stained samples were prepared
in triplicate or duplicate and CD45-FITC/IgG1-PE/CD14-ECD/7-
AAD/CD56-PC7 staining served as control for residual T-cell
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FIGURE 1 | Manufacturing of GMP-grade NK cell products. To optimize
manufacturing of NK cell products three different methods were used for
purification: (A) two T-cell depletion steps using the CliniMACS depletion
program 2.1 (D2.12depl), (B) one T-cell depletion step with the same
program (D2.11depl), and (C) one T-cell depletion step using the CliniMACS
depletion program 3.1 (D3.11depl). Unstimulated leukapheresis products
were collected and CD3+ depletion followed immediately. If two
leukapheresis products were available on day 1 and day 2, both CD3
depleted products were pooled prior to the CD56 enrichment. In A, an
additional T-cell depletion step was ensued. Finally in all cases a CD56+
positive selection was done with the CD3 depleted products using the
CliniMACS enrichment program E1.1.
detection. In addition, a number of samples were labeled with
appropriate combinations of fluorochrome-conjugated mono-
clonal antibodies (MAb) to monitor DCs, the surface expression
of NCRs and CD69, phosphorylation of the signal transducer
and activator of transcription 3 (STAT3) and the protein kinase
AKT. Surface expression of the NCRs NKp30, NKp44, NKp46
on NK cells was quantified in Antibody Binding Capacity (ABC)
units by using the Quantum Simply Cellular kit (Bangs Laborato-
ries, Indianapolis, IN, USA) as described previously (Huenecke
et al., 2010). CD45+CD85k+HLA-DR+CD14−CD16−CD33+
and CD45+CD85k+HLA-DR+CD14−CD16−CD123+ were used
to quantify mDCs and pDCs, respectively (Heinze et al., 2013).
To analyze the samples, we used cytometers with four and
five color detection (Epics™ XL™ and FC500, Beckman Coul-
ter, Krefeld, Germany). Data were analyszed with the aid
of CXP v2.2 software (Beckman Coulter, Krefeld, Germany.)
MAb conjugated with fluorescein isothiocyanate (FITC), phy-
coerythrin (PE), PE-Texas Red tandem (ECD), PE-cyanine-5
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FIGURE 2 | Measurement of absolute viable CD56+CD3− NK cells and
CD3+ T cells. (A). Gating strategy in the leukapheresis product: from left to
right, starting in the first row of plots, the gating strategy follows the ISHAGE
protocol for stem cell enumeration (Keeney et al., 1998), modified for the
peculiarities of NK- and T-cell measurement: plot 1: the region is set to include
all CD45+ events (leukocytes) and is gated on viable cells (plot 2). Therefore,
only 7-AAD negative (vital) events are shown in plot 1. Region: CD45high, SClow
events: lymphocytes. Plot 2: gated on CD45+ events (region, plot 1), the
region is set to discriminate between viable and unstained and non-viable
cells, which are 7-AAD-positive. Plot 3: all viable CD45+ events are shown to
check the lower limit of forward scatter (check FSC). The amorphous region is
created to exclude unspecifically stained debris by low forward scatter signal.
Thus, region WBC includes all viable leukocytes. Plot 4: it displays the
fluorescent signal of the events vs. time and is gated on beads (see plot 5,
beads gate, top right). Region CAL is set to define the signal of Flow-CountTM
fluorospheres and to monitor the occurrence of fluorospheres doublets,
which is less than 5% in this plot. CAL is the calibrator region to automatically
calculate the concentrations of the events in a given gate. Steady sample flow
is monitored here, too. Plot 5 and plot 9: these dot plots show all events and
are used as a visual guide for antigen expression of CD3 and CD56. The
respective CD45 negative region is used to exclude CD45 negative events in
order to reduce the data acquisition. Quadrant 2 can be useful to review the
lower limits of CD45 and CD56 or CD3 expression, and – if necessary – to
correct the position of the regions in plot 1, 6, and 10. Plot 6 and plot 10: the
region includes all viable CD3+ or CD56+ leukocytes and is gated on the
CD45+ region in plot 1. Plot 7 and plot 11: logical AND linkage (intersection) of
regions CD45+ (plot 1), CD3+ or CD56+ (plots 6, 10) and viability (plot 2). The
cluster region is set to include CD45highSClow CD45+, 7-AAD− CD3+ or CD56+
events, respectively and to exclude granulocytes. Plot 8, plot 12, and plot 15:
intersection of the regions from the regions in plots 1, 2, 6 or 10, and 7 or 11,
respectively. The respective region is linked with region check FSC (plot 3) so
that changes in the position of region check FSC will automatically be adopted
by region in the plots of 8, 12, and 15. Region FSC is used to set the lowest
limit for FSC. The thus accepted viable CD3+ T cells (plot 8), viable CD56+ NK
and NK like T cells (plot 12), and the viable CD56+CD3− NK cells (plot 15) are
counted in regions of the plots 8, 12, and 15, respectively. Plot 13: control
gate for showing all, specific and unspecific CD3 antibody binding for the
calculation of sufficient CliniMACS CD3 reagent for the CD3 depletion of the
NK cells. Plot 14: this is used for both enumeration of CD14+ monocytes and
as dump channel to exclude monocytes from all analyses, which is of major
importance to evaluate residual T cells after NK cell purification. (B).
Respective analyses in the purified NK cell products as well as cultured,
expanded NK cells: plot 16 and plot 17: the region is set to include all CD45+
events in accordance to plot 1. Plot 18 and plot 19: discrimination between
viable and dead cells in accordance to plot 2. Plot 20 and plot 21: overview of
CD56+CD3− NK cells, residual CD3+CD56− T cells, and CD56+CD3+ NK like T
cells in accordance to plot 9. Plot 22 and plot 23: the region includes all viable
CD56+CD3− NK cells gated on the CD45+ region (plot 16, 17).
(PC-5), or PE-cyanine-7 (PC-7) were used against the fol-
lowing antigens (clones): CD3 (UCHT1) and (SK7)#, CD14
(RMO52), CD14+CD16 (RMO522+3G8), CD16 (3G8), CD33
(D3HL60.251), CD45 (B3821F4A and J.33), CD56 (N901)
and (NCAM16.2)#, CD69 (TP1.55.3), CD85k/ILT-3 (ZM3.8),
CD123 (107D2), CD335/NKp46 (BAB281), CD336/NKp44
(Z231), CD337/NKp30 (Z25), CD314/NKG2D (ON72), p-STAT-
3 (Tyr705), p-AKT (Ser473) (Beckman Coulter, Marseille, France
exept # BD Biosciences, Heidelberg, Germany).
CYTOTOXICITY ASSAY
The cytotoxic activity of the purified NK cells before and after
IL-2 stimulation was tested against the MHC class I-negative cell
line K562 and, if available, against the patients’ own leukemic cells
using an antibody-based flow cytometric single-platform assay
as described previously (Zimmermann et al., 2005; Kloss et al.,
2007). NK cells and target cells were co-cultured for 4 h at 1:1
up to 10:1 effector:target ratios. Absolute cell counts were cal-
culated using Flow-Count™ fluorospheres as internal standard.
Frontiers in Oncology | Pediatric Oncology May 2013 | Volume 3 | Article 118 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Koehl et al. Clinical grade NK cell manufactouring
Cytotoxicity was defined as the loss of viable target cells in relation
to the mono-cultured control.
KIR AND HLA GENOTYPING
We used a PCR method to detect the presence or absence of
19 killer-cell immunoglobulin-like receptor (KIR) genes (2DL1-
5B, 3DL1-3, 2DS1-5, 3DS1, 2DP1, 3DP1) in the peripheral blood
cells of both, NK cell donors and patients with sequence-specific
primers as described previously (Becker et al., 2003). More-
over, HLA typing was done with sequence-specific probes and
sequence-based typing (SBT) analysis. We then evaluated the
donor-recipient pairs for the presence of KIR – HLA-ligand
mismatches according to the “missing KIR ligand” model.
STATISTICAL ANALYSES
Statistical analyses were performed using GraphPad Prism 5.03
(GraphPad Software, San Diego, CA, USA). Differences between
groups were examined for statistical significance using the
Kruskal–Wallis test with Dunn’s multiple comparisons or an
unpaired t -test. Differences were considered significant when
p< 0.05, p< 0.01, or p< 0.001, indicated as ∗, ∗∗, and ∗∗∗,
respectively.
RESULTS
IMPACT OF CELL PROCESSING ON NK CELL YIELD, PURITY, AND T-CELL
REMOVAL
A total of 40 apheresis products (26 single, 14 pooled prod-
ucts) were immunomagnetically T-cell depleted, either by the
time-consuming, but effective DEPLETION 2.1 program with (A)
two consecutive T-cell depletion procedures (D2.12depl, n= 13), or
(B) by DEPLETION 2.1 program using one T-cell depletion run,
only (D2.11depl, n= 18), or (C) by using the fast DEPLETION 3.1
program (D3.1, n= 9) as indicated in Table 1 and Figure 1.
The mean absolute leukocyte numbers and the percentages of
T and NK cells did not differ between the three groups. Both, start-
ing numbers of absolute white blood cells (WBC) and percentage
of NK cells did not differ between the three groups with median
numbers of 1.9× 1010, 1.9× 1010, and 2.1× 1010 for WBCs and
8.5, 7.5, 7.2% for CD56+CD3− cells. Absolute numbers of NK
cells ranged from 0.67 to 2.98× 109, 0.61 to 4.79× 109, and 0.69
to 6.16× 109, respectively. More than half of the cells were CD3+
T cells (median 51, 56, 55.7%).
After the whole enrichment process, use of D2.1 resulted in
significantly better T-cell depletion than D3.1 Two sequential runs
of D2.12depl or one single run of D2.11depl led to a median T-cell
depletion of log 4.9 (range: 3.9–5.9) or log 4.6 (range: 3.2–5.7),
respectively, compared to log 3.7 (range: 3.2–4.1) using D3.1
(p< 0.001; p< 0.01; Figure 3A). The double depletion proce-
dure yielded residual T-cell percentages of less than 0.1% (median
0.01%) as shown in Table 1. The additional CliniMACS depletion
run took about 1 h, only, because the cell suspension at that point
always contained less than 0.5% CD3+ T cells.
In contrast to the effective T-cell removal, D3.1 was superior
to both, using single or double D2.1 with respect to recovery of
CD56+CD3− NK cells (median NK cell recovery 68 vs. 38% and
41%; p< 0.05; Figure 3B). All in all, the pure processing time on
Table 1 | Percentage and absolute count of NK andT cells using different GMP-grade enrichment procedures for NK cell manufacturing.
(A) Depletion 2.1 (D2.12depl)
2 CD3 depletion steps (n=13)
(B) Depletion 2.1 (D2.11depl)
1 CD3 depletion step (n=18)
(C) Depletion 3.1 (D3.11depl)
1 CD3 depletion step (n=9)
Median (range) Median (range) Median (range)
LEUKAPHERESIS PRODUCT
WBC (×106) 18907 (4762–74162) 19338 (7608–76680) 21027 (13719–47334)
CD56+CD3− NK cells (%) 8.5 (5.4–13.7) 7.5 (2.8–14.9) 7.2 (4.9–15.5)
CD56+CD3− NK cells (×106) 1526 (673–2975) 1701 (612–4790) 1628 (693–6156)
CD3+ T cells (%) 51 (40–67.7) 56 (43.3–68) 55.7 (45.9–63.7)
CD3+ T cells (×106) 10331 (2392–28498) 10056 (3827–43790) 10936 (8594–23557)
AFTER CD3 DEPLETION
WBC (×106) 3822 (982–8560) 5970 (2012–19749) 8356 (4560–20261)
CD5 6 +CD3− NK cells (%) 25 (14–47) 18.9 (6.5–27.1) 17 (10.7–27.8)
CD56+CD3− NK cells (×106) 813 (400–2181) 907 (340–3148) 1091 (607–5613)
CD3 + T cells (%) 0.01 (<0.001–0.08) 0.04 (<0.001–0.29) 0.11 (0.05–0.4)
CD3+ T cells (×106) 0.30 (<0.02–2.61) 1.21 (<0.02–17.12) 7.89 (3.83–16.93)
AFTER CD56 ENRICHMENT
WBC (×106) 0.75 (0.25–1.9) 0.83 (0.3–2.9) 0.99 (0.43–4.5)
CD56 +CD3− NK cells (%) 94.9 (82.5–98.3) 92.2 (70–98.2) 93.4 (91.7–97.3)
CD56+CD3− NK cells (×106) 712 (234–1880) 745 (284–2703) 942 (426–4254)
CD3+ T cells (%) 0.01 (<0.001–0.1) 0.04 (<0.001–0.34) 0.24 (0.07–0.5)
CD3+ T cells (×106) 0.12 (<d. l. –1.50) 0.31 (<d. l. −6.99) 3.72 (0.72–5.52)
CD56 recovery (%) 38 (23–69) 41 (14–76) 68 (40–85)
T-cell depletion (log) 4.9 (3.9–5.9) 4.6 (3.2–5.7) 3.7 (3.2–4.1)
Individual steady-state leukapheresis products: 9 in (A), 13 in (B), and 4 in (C) and pooled products from two leukaphereses: 4 in (A), 5 in (B), and 5 in (C); d. l., detection
limit.
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FIGURE 3 | Impact of cell processing on NK cell yield, purity, andT-cell
depletion. NK cells were enriched by either the depletion 2.1 program in a
double T-cell depletion round using an LS purification set (depletion 2.1, 2
depl. n=13), the same program using only one T-cell depletion round
(depletion 2.1, 1 depl. n=18) or by using the fast depletion 3.1 program with
a DTS purification set (depletion 3.1, 1 depl. n=9). (A) T-cell depletion was
significant lower with the depletion 3.1 program compared to the depletion
2.1 for one or two rounds of T-cell removal. (B) With the depletion 3.1 program
a significant higher NK cell recovery was reached compared to the depletion
2.1. (C) The NK cell manufacturing on the CLINIMACS device was three to
four times higher using the depletion 2.1 program compared to the depletion
3.1. (D,E). Neither purity and recovery did not differ among the three used
purification techniques. (F). After the final CD56 enrichment step a large
range of concomitant CD14+ monocytes (0.3–29.1%) in the respective
CD56+CD3− NK cell product was observed, which did not differ between the
used purification techniques.
the CliniMACS device was three to four times longer for D2.1
compared to D3.1 (Figure 3C).
Overall, NK cell enrichment led to a final median number of
7.59× 108 CD56+CD3− cells with both median purity of 94%
and viability of 94%. Purity and viability did not differ among
the three enrichment protocols (Figures 3D,E). The overall purity
ranged from 70 to 98.2% CD56+CD3− NK cells. The major popu-
lation of contaminating cells in the purified NK cell products were
CD14+ monocytes ranging from 0.2 to 29.6% (Figure 3F). Other
than that, we found myeloid and pDCs ranging from 0.1 to 3.8%
(data not shown).
EXPANSION, ACTIVATION, AND UNFREEZING OF DONOR DERIVED NK
CELLS
Seventeen NK cell products were further IL-2 stimulated for 10–
12 days. During the first 4–5 days of IL-2 stimulation, vital NK
cell counts decreased by 30–65% (Figure 4A). Afterward, NK cell
counts started to recover. However, we found a wide variation in
the NK cell expansion rate among different donors. While the NK
cells of two donors expanded vigorously (median 30-fold), those
of another three donors recovered to starting NK cell numbers at
the end of the expansion period, only (Figure 4A). NK cells of 12
donors expanded moderately to a median fourfold (range: twofold
to eightfold). Of note, NK cells tend to grow in clusters (Figure 4A)
and need to be singularized carefully for correct quantification,
yielding a source for underestimating the true numbers.
Natural Killer cell expansion and intracellular signaling of
p-STAT-3 or p-AKT did not differ using IL-2 alone or in com-
bination with IL-2 and IL-15 (Figure 4B). Phosphorylation of
the intracellular signaling molecules STAT3 and AKT was aug-
mented in activated NK cells compared to unstimulated NK
cells. Initially, we found relatively uniform distribution of the
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FIGURE 4 | Expansion, activation, and unfreezing of CD56+CD3− NK cells.
(A) During the first 4–5 days after IL-2 stimulation, vital NK cell count
decreased by 30–65% and started to recover thereafter. Median expansion
rate was four times for the allogeneic NK cells of 12 donors, while NK cells of
two donors showed a high expansion rate (median 30-fold) and NK cells of
three donors reached the starting NK cell count only at the end of the
expansion rate. (B) Expansion rate during stimulation with 10 ng/ml IL-15 and
100 U/ml IL-2 did not differ from those after stimulation with 1000 U/ml IL-2
only. Intracellular signaling (p-STAT 3 and p-AKT) was increased in stimulated
compared to unstimulated NK cells but did not differ between IL-2 or IL-2/IL-15
activation. (C) Although the major cytotoxic CD56dimCD16pos and the minor
immunoregulatory CD56brightCD16neg NK subpopulation showed a
homogeneous distribution after NK cell enrichment, this changed during IL-2
stimulation. After activation large differences between CD16pos and CD16neg
NK subpopulations were seen among the NK cells of various donors. (D) After
NK cell purification residual T cells consists of 3/4 of CD3+CD56+ NK like T
cells and of 1/4 CD3+CD56− T cells, a ratio which changed only slightly during
IL-2 stimulation. (E) Both, viability and recovery was higher after unfreezing of
Il-2 stimulated compared to unstimulated NK cells and was highly significant
for the NK cell recovery.
major cytotoxic CD56dimCD16+ and the minor immunoregula-
tory CD56brightCD16dim/− NK cell subpopulations that changed
during IL-2 stimulation as shown in Figure 4C. However, there
was a marked variation of the proportions among donors at the
end of expansion showing (i) both CD16+ and CD16− NK cells,
(ii) mainly CD16− or (iii) CD16+ NK subpopulations, only.
The residual CD3+ T cells at the beginning of IL-2-stimulation
consisted to 72± 11% of CD3+CD56+ NK-like T cells and to
25± 4% of CD3+CD56− T cells (Figure 4D). This distribution
changed only slightly during IL-2 stimulation up to 66 and 33%,
respectively. Moreover, the percentage of residual T cells did not
increase as shown exemplarily in Figure 2B.
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The viability of cryopreserved NK cells after unfreezing was sig-
nificant higher for IL-2 stimulated NK cells (median 60%, range:
25–91%) compared to unstimulated NK cells (median 30%, range:
17–55%) as shown in Figure 4E. The difference was even meaning-
ful and highly significant for the NK cell recovery after unfreezing
resulting in a median of 84% (range 75–92%) for IL-2 stimu-
lated NK cells compared to a median of 22% (range 8–44%) for
unstimulated NK cells, respectively.
As opposed to the large quantities of monocytes contained at
the start of stimulation (>4% in half and >10% monocytes in
another 3 of 40 cell suspensions after immunomagnetic isola-
tion, Figure 3F, the content of monocytes decreased dramatically
during IL-2 stimulation attributable to adhesion to the bags.
Therefore, the purity of the final suspensions increased to >98%
CD56+CD3− NK cells after stimulation.
NK CELL CYTOTOXICITY
Natural Killer cell cytotoxic activity of both the freshly isolated NK
cells of all donors (n= 40) and of the IL-2 stimulated NK cells of 17
donors was tested against K562 cells. Additionally, when available,
the NK cells of five donors were tested against the respective recipi-
ent’s leukemic cells. Unstimulated NK cells killed a median of 28%
and of 58% target cells in the 1:1 and 10:1 NK:K562 ratios, respec-
tively (Figure 5A). The lytic NK cell activity increased after IL-2
stimulation, reaching a median cytotoxicity of 64 and 92% in the
two ratios. Concomitantly, the surface expression of the activat-
ing receptors CD69, NKG2D, and the NCRs NKp30, NKp44, and
NKp46 was up-regulated (Figures 5B,C). Both, a significant IL-2
driven increase of the percentage of NK cells expressing NCR and
of the surface density of NCR were shown. Further, the density of
NKG2D increased as found by ABC p< 0.01 or p< 0.001. Interest-
ingly, the three unstimulated NK cell suspensions with monocytes
of >10% also exerted higher cytotoxic activity against K562 cells
(70 and 41%) in the 10:1 and 1:1 effector:target ratio compared to
those with a smaller amount of monocytes reaching a median NK
cell cytotoxicity of 58 and 27%, respectively (Figure 5A). However,
this was not statistically significant.
We also investigated the interaction between the haploidenti-
cal NK cells and the leukemic cells of five children (three with
ALL, 2 with AML), Again, a high percentage of monocytes led
to enhanced NK cell lysis of the leukemic cells (1 ALL, 1 AML)
in both the 10:1 and 1:1 effector:target ratio compared to those
cell suspensions containing no or only a small amount of mono-
cytes (Figure 5D). We measured a killing of 31 and 16% in the
10:1 and 1:1 ratio, respectively, compared to 21 and 4.5% for the
three NK cell suspensions (2 ALL, 1 AML) containing less than
10% monocytes. This difference was significant in the 1:1 ratio
(Figure 5D; p< 0.05). This increased cytotoxicity seemed to be
independent of both the MHC-I expression of the leukemic cells
and the KIR mismatch in GvL direction. Interestingly, in both
cases with a higher killing activity of unstimulated NK cells, no
KIR mismatch was demonstrated between donor and recipient
as opposed to the three pairs with lower killing that displayed
one or two KIR ligand mismatches (Figure 5E). IL-2 stimu-
lated NK cells led to an improved killing activity against patients’
leukemic cells for both donor:recipient pairs with and without KIR
mismatch.
In these, both patients with ALL lacked one HLA-C ligand for
donor group I KIRs, while the AML patient had a missing HLA-C
donor KIR group II ligand and a missing HLA-A11. Moreover,
in all 5 investigated samples, the leukemic cells showed a high
MHC-I expression compared to K562 cells (Figure 5E), suggest-
ing that they would be resistant against NK cell lysis. Nevertheless
cytotoxicity of the haploidentical donor NK cells with>10% con-
comitant monocytes against the ALL (2) sample was moderately
high, although the leukemic blasts reached the highest MHC-I
expression and a KIR mismatch was lacking.
DISCUSSION
Clinical-scale collection, enrichment, activation, and expansion
of purified NK cells is feasible. However these procedures are
time-consuming and expensive, need particular skills, and must be
performed according to a GMP-compliant protocol. To date, NK
cell trials and ongoing clinical phase I/II studies have shown the
feasibility of using freshly purified or IL-2-activated donor NK cells
for the treatment of high-risk patients suffering from leukemia or
tumors in both non-transplant settings and after haploSCT as an
additional immunotherapy (Koehl et al., 2004; Passweg et al., 2004;
Miller et al., 2005; Rizzieri et al., 2010; Rubnitz et al., 2010; Curti
et al., 2011; Nguyen et al., 2011; Stern et al., 2013). NK cell doses
ranged from 1× 106/kg to 1× 108 CD56+CD3− NK cells/kg BW,
very often with less than 5× 104 CD3+ T cells/kg BW (Passweg
et al., 2006; Huenecke et al., 2010; Rizzieri et al., 2010; Rubnitz
et al., 2010; Brehm et al., 2011; Stern et al., 2013). These first
immunotherapy trials showed that NK cells can be administered
without immediate adverse events, that they were well-tolerated
by the patients and did not induce severe GvHD. However, some
cases of GvHD >grade II have been observed after NK cell infu-
sion, which seemed to be associated with a less efficient T-cell
depletion. Whether GvHD is attributable to contamination by T
cells or is due to the effects of NK cells cannot be determined
based on these clinical data so far. But the fact that – at least in
some cases of GvHD – the T-cell content was higher than in cases
without GvHD, seems to favor a T-cell effect.
Thus, advances in NK cell therapy after haploSCT requires
both, refined manufacturing procedures to obtain NK cells prod-
ucts with a minimum of residual T cells and the development of
dependable methods to obtain adequate numbers of effector cells.
In the present study we report on 40 GMP-conform NK cell prod-
ucts manufactured by using immunomagnetic CD3 T-cell deple-
tion, followed by a CD56 cell enrichment step with modifications
in the T-cell removal. The median T-cell depletion was significantly
better using a single or double procedure of the time-consuming
depletion program depletion D2.1 compared to the fast depletion
program D3.1, but median recovery of CD56+CD3− NK cells was
inversely correlated. A number of various studies have shown that
clinical-scale NK cell isolation from non-stimulated leukapheresis
products, using CD3+ cell depletion/CD56+ cell enrichment, lead
to highly purified CD56+CD3− NK cell products with a median
purity ranging from 90 to 98.6% (Iyengar et al., 2003; Lang et al.,
2003; Passweg et al., 2004; Koehl et al., 2005; McKenna et al., 2007;
Meyer-Monard et al., 2009; Rizzieri et al., 2010). The high NK cell
purity and extensive T-cell depletion was possible at the expense of
considerable loss of NK cells during isolation. The final recovery
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FIGURE 5 | Cytotoxicity of NK cells against K562 and patients’ leukemic
cells. (A) Donor NK cell cytotoxicity against K562 cells was significantly
increased after IL-2 stimulation compared to unstimulated NK cells and also
seemed to be slightly increased for unstimulated NK cells if the purified NK
cell products include >10% concomitant monocytes. (B) IL-2 stimulation led
to a significant increase in the percentage of NK cells with the natural
cytotoxicity receptors NKp30, Nkp44, NKp46, and the activating receptor
CD69. (C) In addition IL-2 stimulation led to a significant up-regulation of
NKp30, NKp44, NKp46 on NK cells as well. (D) Concomitant monocytes
(>10%) in the purified NK cell products increased donor NK cell cytotoxicity
against the haploidentical leukemic blasts of pediatric patients with leukemia
(1 AML, 1 ALL) significantly compared to those with a low amount or no
monocytes (1 AML, 2 ALL).This improved cytotoxicity was compared to those
of IL-2 stimulated NK cells against the respective haploidentical leukemic
cells. (E) The leukemic blasts of five pediatric patients (3ALL, 2 AML), in which
the interaction between the haploidentical donor NK cells and the respective
individual patients´ leukemic cells was investigated, all showed a significantly
increased high expression of MHC-I (black bars, measured as antibody binding
capacity) compared to the MHC-I negative K562 cells. In those, in case of one
ALL and one AML no KIR ligand mismatch between the haloidentical donor
NK cells and the respective leukemic blasts could be demonstrated.
Interestingly, cytotoxicity of unstimulated NK cells (gray bars) was found to be
slightly higher in case of no compared to those with KIR mismatch. IL-2
stimulated NK cells showed an improved cytotoxicity (white bars).
of CD56+CD3− NK cells ranged between 20 and 58% in these
different studies and we could demonstrate improved recovery of
NK cells to a median of 68% using the fast depletion program
3.1. Overnight storage of the leukapheresis product resulted in a
greater loss of NK cells during the NK cell selection process com-
pared to processing of fresh harvests as we could show previously
(Meyer-Monard et al., 2009). For over night storage cells have
been placed in the GMP facility on a waver at 4˚C in the dark. A
much higher NK cell recovery was also obtained by using only a
CD3+ cell depletion step, without further CD56+ cell enrichment.
However, such a product was associated with low purity and less
T-cell depletion (McKenna et al., 2007, 2012; Koepsell et al., 2013).
Similarly, the final T-cell number was much higher if a CD56+
cell selection was used alone (Rizzieri et al., 2010). In contrast,
the two-step NK cell product manufacturing described here led to
efficient T-cell depletion for haploSCT, and this could be further
increased by performing the CD3+ cell depletion step twice. A
residual T-cell contamination between below the detection limit
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(0.001%/0.1/µl) and 0.09% in the final product allows the infu-
sion of NK cell products of more than 1.0× 107 CD56+CD3− NK
cells/kg BW with less than 5.0× 104 CD3+ cells/kg BW, and often
even less than 2.5× 104 CD3+ T cells/kg BW (Brehm et al., 2011;
Stern et al., 2013). Therefore, for future NK cell purification, we
recommend a combination of the fast depletion program 3.1 in
order to deplete most of the T cells and if necessary followed by a
second round or T-cell depletion using the effective depletion pro-
gram 2.1 which is not time-consuming for a starting percentage
of 0.5% T cells.
The objective of NK cell purification is not only to remove
potentially unwanted T cells, but also to enable activation and
expansion of the NK cells. Indeed, enriched NK cells can be infused
without any additional manipulation, or after overnight culture
with a high-dose of IL-2. They can also be expanded with IL-2 or
other cytokines, such as IL-15, alone or in combination for two to
several weeks in cell culture bags or in a bioreactor (Koehl et al.,
2005; Sutlu et al., 2010). Similarly, it is possible to expand single
KIR+ NK cells (Siegler et al., 2010). To date, there is evidence that
a combination of multiple cytokines, such as IL-2, IL-12, IL-15,
Il-18, and IL-21, may further increase cytotoxic activity of NK
cells. Other protocols reach a very high NK cell expansion rate
using genetically modified K562 cells (Shook and Campana, 2011;
Lapteva et al., 2012). In addition to NK cell enrichment from leuka-
pheresis products, NK cells can also be generated from cord blood
(Spanholtz et al., 2010). However, there are several limitations
in regard to GMP-conform protocols such the lack of marketing
authorization for the respective clinical-scale cytokines or the use
of gene-manipulated tumor cells.
Therefore, clinical-scale in vitro expansion has two aims, to
activate the selected CD56+CD3− cells, and to increase the total
number of NK cells. In the present study we present our clinical-
scale protocol that enables the generation of NK cells in a closed
bag system conforming to GMP guidelines. We could show that
highly enriched CD56+CD3− NK cells could be expanded under
the influence of 1000 U/ml IL-2, although we observed a lag of 3–
4 days before the remaining NK cells started to proliferate. Between
day 4 and 6, expansion occurred, but with marked differences
in the proliferation rate among 17 NK cell donors. While NK
cells of two donors reached the starting NK cell level only, in
12 cases a median fourfold and in two cases a 30-fold increase
of CD56+CD3− NK cells could be observed after 12 days. This
reflects the strong differences with regard to biological material of
various donors. Although NK cells were viable immediately after
purification (median 94%), the vital NK cell count decreased by
30–65% during the first 3–4 days following IL-2 stimulation, but
viability recovered completely toward the end of the expansion
period. Purity of the CD56+CD3− NK cells was higher at the end
of the expansion period (>98%) compared to the first analysis
performed directly after purification. Interestingly, this effect was
due to the amount of concomitant monocytes (or other antigen-
presenting cells like DCs) in the NK cell products after purification,
but it was lost during cell expansion. Importantly, no overgrowth
of the remaining T cells was observed during expansion and acti-
vation with IL-2. The phenotype of the residual T cells did not
change significantly during expansion regarding to CD56+CD3+
NK-like T cells and CD3+CD56− T cells. In contrast, we found
large differences between CD16+ and CD16dim/− NK cell sub-
populations at the end of the expansion period compared to a
homogeneous distribution between immunoregulatory and cyto-
toxic NK cells after purification as described previously more in
detail (Huenecke et al., 2010).
As cytotoxic quality control, in our present study unstimulated
NK showed a sufficient lytic activity against the MHC-Inegative
cell line K562, that significantly increased under the influence
of IL-2. The demonstrated up-regulation of the NCRs NKp30,
NK44, NKp46, the activating receptor CD69 as well as of NKG2D,
and the increase in intracellular pSTAT3 and AKT signaling might
explain the improved NK cell cytotoxicity when cultured in IL-2.
Interestingly, this strongly increased NCR and NKG2D expres-
sion overrode important inhibitory mechanisms which allowed
IL-2 activated haploidentical NK cells to lyse MHC-Ipositive tar-
gets as we demonstrated for the respective leukemic blasts of five
pediatric patients suffering from AML and ALL. In contrast, we
expected no or a very weak cytotoxicity of unstimulated NK cells
against MHC-Ipositive leukemia. Surprisingly, in two cases a sig-
nificantly higher NK cell cytotoxicity of unstimulated NK cells
against these respective MHC-Ipositive leukemia’s was found if the
cell count of concomitant monocytes was above 10% of the cell
product. Most importantly though, this improved lysis occurred
in donor:recipient pairs without KIR mismatch in GvL direction.
Similarly, we had demonstrated previously an increased cytotoxic-
ity of haploidentical unstimulated NK cells with concomitant DCs
and monocytes against neuroblastoma compared to IL-2 stimu-
lated NK cells (Kloess et al., 2010). Our observations indicate that
in addition to the well-known balance between inhibitory and acti-
vating receptors to lyse MHC-Inegative targets by unstimulated NK
cells, other mechanism might override the influence of inhibitory
receptors such as KIRs leading to (i) changed balance for unstimu-
lated NK cells under the influence of antigen-presenting cells and
(ii) enhanced effects of activating signals only if activated NK cells
cause also lysis of MHC-Ipositive targets. However our given exam-
ples are very few and need further investigations. Nevertheless,
in line with our results are observations of Obeidy and Sharland
(2009) and Vivier et al. (2012) reviewing the importance of both
up-regulation of NKG2D and the NK cell environment which can
lead to killing of MHC-Ipositive targets by NK cells.
Future studies should improve NK cell immunotherapy by
increasing the understanding of the conditions leading to tumor
cell killing by NK cells, by increasing the cytotoxicity of NK
cells against various malignancies, and by optimizing the sched-
ule of the NK administration based on results of ongoing phase
I/II studies. Given the plausible benefit of IL-2-stimulated NK
cells compared to freshly isolated, unstimulated NK cells with
regard to cytotoxicity, it may be possible to increase the killing
capacity of NK cells by improving the cross-talk with antigen-
presenting cells like DCs or simply monocytes. DCs and NK
cells specialize in complementary functions, including IL-12 or
IFN-α/β secretion and antigen presentation for the former, and
IFN-γ secretion and killing of infected or tumor cells for the lat-
ter. Thus, the outcome of NK-DC crosstalk is likely to increase
lytic activity against malignancies compared to NK cell cytotox-
icity alone (Walzer et al., 2005; Pallandre et al., 2008; Wehner
et al., 2009; Jacobs and Ullrich, 2012). Additional investigations are
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necessary to develop strategies to overcome tumor immune escape
mechanisms. In pediatric patients with neuroblastoma tumor
cells escaped from immune surveillance by releasing of soluble
MICA (ligand MHC class I-chain-related gene A) compromising
NKG2D-dependent NK cell cytotoxicity. Elevated sMICA levels
in those patients’ plasma correlated significantly with impaired
NK-cell mediated cytotoxicity of the infused haploidentical donor
NK cells (Kloess et al., 2010). This could be overcome in part by
higher numbers of NK cells which stress the importance of devel-
oping improved NK cell purification and expansion techniques,
especially if multiple NK cell applications are required. Options
may encompass development of MAb against sMICA or genetic
engineering of NK cells by introduction of chimeric receptors for
tumor retargeting (Esser et al., 2012). Other strategies focus on
enhancing tumor cell recognition by using small interfering RNA
to silence inhibitory receptors or by expansion of tumor-reactive
NK cells.
In order to improve NK cell purification we recommend a com-
bination of the fast depletion 3.1 program followed by a second
run of T-cell depletion using the slow, but effective depletion 2.1
program for removing of residual T cells securely. After the final
CD56 enrichment step for the following GMP-conform expansion
of CD56+CD3− NK cells, IL-2 activation might be improved by
the additional use of antigen-presenting cells such as monocytes
or DCs.
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